JPSBR: Volume 5, Issue 3: 2015 (249-253) ISSN NO. 2271-3681 Patel N A. et al 249 ABSTRACT: Helicobacter pylorus (H. pylori) is one of the most common pathogenic bacterial infections and is found in the stomachs of approximately half of the world’s popula- tion. It is the primary known cause of gastritis, gastro- duodenal ulcer disease and gastric cancer. However, combined drug therapy as the general treatment in the clinic, the rise of antibiotic-resistant bacteria, adverse reactions and poor patient compliance are major ob- stacles to the eradication of H. pylori . Oral site-specific drug delivery systems that could increase the longevity of the treatment agent at the target site might improve the therapeutic effect and avoid side effects. Gastro- retentive drug delivery systems potentially prolong the gastric retention time and controlled/sustained release of a drug, thereby increasing the concentration of the drug at the application site, potentially improving its bioavailability and reducing the necessary dosage. KEY WORDS: Review on: Gastro-Retentive Floating Drug Delivery System for the Treatment of H.Pylori Infection Article history: Received 14 Jan 2015 Accepted 15 Feb 2015 Available online 01 May 2015 Citation: Patel N A, Shah S, Shah N, Review on: Gastro-Retentive Floating Drug Delivery System for the Treatment of H.Pylori Infection J Pharm Sci Bioscientific Res. 2015 5(3):249- 253 For Correspondence: Mr.Patel Nixipt L.J institute of pharmacy, Near nagdev kalian mandir. Okaf village, Sarkhej-gandhinagar highway, Ahmedabad , India Email: nixipt.patel@gmail.com (www.jpsbr.org) INTRODUCTION: Helicobacter pylori (H. pylori) is one of the most common pathogenic bacteria and is found in the stomachs of more than half of the world’s population. H. pylori infections are the primary known cause of gastritis, gastro-duodenal ulcer disease and gastric cancer [1] . Even after 30 years of experience in H. pylori treatment, clinicians and researchers are still exploring the ideal regimens for clinical application [2] . Although H. pylori has been shown to be highly sensitive to a single antimicrobial agent in many antibacterial in vitro trials, in clinical the eradication rate of H. pylori is still low [3] . There are three explanations for this finding: first, many antibiotics are unstable in the low pH of gastric acid; second, the concentration of the drug in the deep gastric mucus where the bacterium lives is too low and third, the amount of time that the antibiotic resides in the stomach is too short [4] . Triple therapies consisting of the combined use of antibiotics are frequently used in the clinical treatment of H. pylori associated with gastro- duodenal disease. However, the high level of antibiotic resistance by H. pylori, drug side effects and poor patient compliance are major drawbacks of multidrug therapy. For these reasons, prolonging the gastric residence time of the drug while improving its stability in gastric acid is a logical approach to overcome these issues. Gastro-retentive dosage forms are one of the oral site-specific drug delivery systems that have been proposed. Nixipt A Patel* 1 , Shreeraj Shah 2 , Nihar Shah 3 1. M.Pharm, Pharmaceutical Technology, L.J Institute of Pharmacy, Sarkhej, Ahmedabad, Gujarat, India 2. Head Of Department of Pharmaceutical Technology, L.J Institute of Pharmacy, Sarkhej, Ahmedabad, Gujarat, India 3. Assistant Professor, Department of Pharmaceutical Technology, L.J Institute of Pharmacy, Sarkhej, Ahmedabad, Gujarat, India